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Background: Recent studies have suggested that a functional cure for HIV-1 infection, purportedly resultant from
allogeneic bone marrow transplantation, may be possible. Additionally, the first such patient was treated with
whole-body irradiation, immunosuppressants, and the chemotherapeutic, cytarabine. However, the precise role of
the coinciding medical interventions in diminishing detectable HIV reservoirs remains unstudied.
Findings: In this article, we demonstrate that the immunosuppressants, mycophenolic acid and cyclosporine, and
the chemotherapeutic, cytarabine, are potent antiretroviral agents at clinically relevant dosages. These drugs
strongly inhibit HIV-1 replication in a GFP indicator T cell line and peripheral blood mononuclear cells (PBMC).
Conclusions: Our study suggests that certain clinical immunosuppressants and chemotherapeutic agents may act
combinatorially to inhibit HIV infection. Additionally, chemotherapy-mediated cytotoxicity may also affect the
stability of viral reservoirs. Thus, further study is needed to examine potential therapeutic value of these
interventions in patients.
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Materials and methods
Supplementary Materials and Methods can be found in
Additional file 1.
In 2009, a report described the first patient (the Berlin
patient) to be possibly cured of HIV infection [1]. This HIV
patient also presented acute myeloid leukemia, which was
treated with allogeneic stem cell transplantation from a
donor lacking functional HIV CCR5 coreceptor expression
[1]. As of this publication, and four years after removal
of Antiretroviral Therapy (ART), the patient exhibits
undetectable plasma mRNA and viral reservoirs [2]. This
unique case led to the speculation that it is possible to
functionally cure HIV through mutagenesis of CCR5 [2,3].
More recently, two patients in Boston, as was announced
at the 19th International AIDS Conference, have undergone
similar bone marrow transplantation, with indications of* Correspondence: ywu8@gmu.edu
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reproduction in any medium, provided the orpossible diminishment of viral reservoirs [4]. However, the
allogeneic hematopoietic stem cells given to the Boston
patients were derived from donors that express functional
CCR5 receptors. This raises the question in regards to
what actually may have caused the decay of viral reservoirs
in the Berlin patient. Common procedures among these
patients include whole-body irradiation, chemotherapy,
and immunosuppressant treatment, and it is possible
that some of these procedures may have contributed to
reduction of viral reservoirs [1,2]. Significantly, as the
invasiveness of bone marrow transplantation renders it
inapplicable for most HIV patients, illustration of the
clinical benefits of these pharmacological interventions
may lead to a novel methodology for HIV reservoir
elimination.
In this article, we tested possible HIV-inhibitory effects
of the chemotherapeutic agent and immunosuppressants
given to the Berlin patient. The immunosuppressants
mycophenolate mofetil (MMF) and cyclosporine were
given to the patient to prevent rejection of the allogeneic
stem cell transplant, whereas the chemotherapeutic
agent cytarabine was utilized to kill leukemic cells. ToLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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replication, a GFP indicator cell line, Rev-CEM, [5,6]
was utilized. Briefly, cells were treated with MMF at the
indicated dosages (Figure 1A), followed by infection with
HIVNL4-3. At 48 hours post-infection, cells were analyzed
for GFP expression, which measures the degree of HIV-1
replication. Infected cells were also stained for apoptosis
with propidium iodide (P.I.) during flow cytometry to
exclude drug cytotoxicity so that GFP expression will
be measured only in the viable cell population. We


























































Figure 1 MMF inhibits HIV-1 replication in Rev-CEM. (A) Rev-CEM GFP
2 hours prior to infection with 200 ng HIVNL4-3 for two hours. Cells were w
exclude cytotoxicity, cells were also stained with propidium iodide (P.I.) and
(B) The effect of MMF on HIV replication as a function of concentration attested dosages (Figure 1A and 1B) (48 hours post-infection),
in agreement with a previous report [7,8]. Notably, MMF
inhibited HIV-1 replication at clinically relevant dosages
(1–10 μM) [9].
Similarly, cyclosporine-mediated HIV-1 inhibition
was measured as above (Figure 2A). However, no such
inhibition was observed at any of the indicated dosages
(Figure 2B). To the contrary, slight enhancement was
observed in all the dosages tested. As the effects of
cyclosporine A on HIV replication are markedly
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indicator cells were treated with the indicated MMF concentration for
ashed and cultured for 48 hours, and analyzed with flow cytometry. To
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Figure 2 Cyclosporine does not suppress HIV-1 replication in Rev-CEM. (A) Rev-CEM GFP indicator cells were treated with the indicated
cyclosporine concentration for 2 hours prior to infection with 200 ng HIVNL4-3 for two hours. Cells were washed and cultured for 48 hours, and
similarly analyzed with flow cytometry as described in Figure 1A. (B) The effect of cyclosporine on HIV replication as a function of concentration
at 48 hours post-infection.
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inhibition may not be observable utilizing this HIV Rev-
dependent indicator cell line [10].
Cytarabine (Ara-C), the major chemotherapeutic agent
administered to the Berlin patient, was also assayed for
antiretroviral activity as above (Figure 3A). At all indicated
dosages, cytarabine inhibited HIV replication (Figure 3B).
Importantly, Ara-C inhibited HIV at the therapeutic doses
(200 nM – 50 µM) [11]. More significant inhibition was
observed at higher dosages (Figure 3B).
To confirm these findings, we used a complementary HIV
Rev-dependent reporter cell, Rev-CEM-Luc, which expresses
luciferase following HIV infection. We observed drug
dosage-dependent inhibition of HIV-mediated luciferaseactivity (Figure 4A). The Rev-CEM-Luc cell is more quanti-
tative in measuring inhibition of HIV, because the luciferase
activity reflects the overall viral activity. On the other hand,
Rev-CEM measures GFP cell percentage which only reflects
the relative numbers of cells infected. These two reporter
systems complement each other, as Rev-CEM-Luc, although
more quantitative, cannot easily measure the number of
HIV+ cells, and possible drug cytotoxicity.
To further confirm these results in primary blood
cells, we isolated PBMCs from healthy donors and
treated cells with inhibitors to determine inhibition of
HIV replication. For HIV infection of PBMC, cells were
pre-activated with PHA plus IL-2 for 24 hours. One mil-
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Figure 3 Cytarabine inhibits HIV-1 replication in Rev-CEM. (A) Rev-CEM GFP indicator cells were treated with the indicated cytarabine
concentration for 2 hours prior to infection with 200 ng HIVNL4-3 for two hours. Cells were washed and cultured for 48 hours, and similarly
analyzed with flow cytometry as described in Figure 1A. (B) The effect of cytarabine on HIV replication as a function of concentration at 48
hours post-infection.
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presence of the reagents. Infected cells were washed and
resuspended in 1 ml of fresh medium with PHA plus
IL-2, and the reagents added. Inhibition of HIV replication
was measured by the decrease of HIV p24 release in the
supernatant. As shown in Figure 4B, Cytarabine exhibited
inhibition of HIV at all dosages tested. Particularly, it com-
pletely inhibited HIV at dosages above 10 μM, dosages that
are clinically achievable during chemotherapeutic admin-
istration [11]. Mycopheonolic Mofetil exhibited similar
inhibition at all indicated dosages (Figure 4C), largely re-
capitulating previously reported data [7]. Similarly, exquisite
inhibition of HIV-1 was attained with cyclosporine atall concentrations tested, including those that were
subtherapeutic [12]. We also measured the cytotoxicities of
these drugs in PMBC. Cells were identically activated and
treated with these drugs, and apoptotic cells were measured
by propidium iodide staining. As shown in Figure 4E, high
dosages of the chemotherapeutic drug cytarabine showed
cytotoxicity in PMBC, whereas the other two drugs have
no detectable cytotoxicity at all the dosages tested. The
inhibition of HIV replication by cytarabine likely resulted
from direct killing of HIV-infected PBMC.
The diminishment of viral rebound exhibited by the
Berlin patient, as is currently indicated, likely resulted








































































































































































Figure 4 Cytarabine, mycophenolic acid, and cyclosporine inhibit HIV-1 replication in Rev-CEM-Luc and PBMC. (A) Rev-CEM-Luc
indicator cells were treated with the indicated drugs for 2 hours prior to infection with HIVNL4-3 for two hours. Cells were washed and
cultured for 48 hours, and analyzed for HIV-dependent luciferase activity. (B to D) PMBCs were purified from healthy donors. For HIV
infection, cells were pre-activated with PHA plus IL-2 for 24 hours. One million cells were treated with each of the reagents for 2 hours, and
then infected with HIV-1 (250 ng p24) for 2 hours in the presence of the reagents. Infected cells were washed and resuspended in 1 ml of
fresh medium with PHA plus IL-2, and the reagents added. Additional PHA plus IL-2 were added every 48 hours. Supernatant was taken for
measuring viral p24 release by ELISA. (B) Cytarabine dosage-dependent inhibition of HIV-1 infection of PBMC. (C) MMF dosage-dependent
inhibition of HIV infection of PBMC. (D) Cyclosporine dosage-dependent inhibition of HIV infection of PBMC. (E) To measure drug
cytotoxicity, PMBC were also stained with propidium iodide (P.I.) and measured with flow cytometry. Shown are results at day 10 post
drug treatment.
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chemotherapy (cytarabine), immunosuppression (anti-
thymocyte globulin, cyclosporine, and MMF), whole-
body irradiation, allogeneic stem cell transplantation,
and some degree of graft-versus-HIV immunoreactivity
[2]. In this paper, we report the potent antiretroviral
activity of cytarabine in an indicator T cell line, REV-CEM.
Cytarabine also diminished HIV-infected PBMC likely by
direct killing of infected cells. Furthermore, we recapitulate
findings of the antiretroviral activity of cyclosporine
and MMF in PBMC culture. Together, our results
indicate that there is a possibility that a combined use of
irradiation, drug-mediated immunosuppression, ART, and
chemotherapy-induced cytotoxicity may lead to viral
suppression and synergistically increased the decay of viralreservoirs. The therapeutic potential of these treatments, in
the absence of transplantation, on viral reservoirs deserves
further clinical investigation.Additional file
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